Abstracts tagged "SLE"

Abstract Number: 936 • 2018 ACR/ARHP Annual Meeting
Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
Takayuki Katsuyama¹, Hao Li¹, Denis Comte², Michael W. Mosho³, Andrew R. Gillooly³, George C Tsokos⁴ and Vaishali R. Moulton¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Rheumatology, Department of Medicine, Boston, MA, ³Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling and cytokine production, and aberrant numbers and/or function of regulatory T…
Abstract Number: 1681 • 2018 ACR/ARHP Annual Meeting
Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
Chengappa KG¹, Gunjan Kumar², Swaminathan R P³ and Vir Singh Negi¹, ¹Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, ²Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, ³Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India
Background/Purpose: A new classification criteria for SLE was proposed at the ACR/ARHP 2017 annual meet. The aim of this study was to compare the performance…
Abstract Number: 2111 • 2018 ACR/ARHP Annual Meeting
Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow
Lin Gao, Mary O'Connell, Jennifer Anolik and R. John Looney, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: SLE patients are especially vulnerable to corticosteroid induced avascular necrosis. While it is appreciated that multiple factors contribute to AVN, the bone-fat axis in…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 467 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
Ohoud AlAhmed¹, Vidya Sivaraman², Melissa Moore-Clingenpeel³, Stacy P. Ardoin⁴ and Sharon Bout-Tabaku⁵, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, The Ohio State University, COLUMBUS, OH, ³Research, Nationwide Children's Hospital, Dublin, OH, ⁴Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: The co-occurrence of autoimmune disorders (AI) with systemic lupus erythematosus (SLE) in adults is associated with poor disease outcomes. We describe the co-occurrence of…
Abstract Number: 938 • 2018 ACR/ARHP Annual Meeting
Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
Noa Schwartz¹, Susan Chyou², Thomas Li³, William D. Shipman^2,4,5 and Theresa T. Lu³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, ⁵Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY
Background/Purpose: Proper function of lymphatic vessels is needed to limit the magnitude and duration of tissue inflammation. Chronic inflammatory states such as obesity and psoriasis…
Abstract Number: 1685 • 2018 ACR/ARHP Annual Meeting
IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
Elena Grau Garcia¹, Francisco Miguel Ortiz-Sanjuán¹, Cristina Alcañiz Escandell¹, Karla Arevalo Ruales¹, Inmaculada Chalmeta Verdejo¹, Marta De la Rubia Navarro¹, Jorge Juan Fragio Gil¹, Roxana Gonzalez Mazario¹, Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Elvira Vicens Bernabeu¹, Carmen Najera Herranz¹, Ines Canovas Olmos¹, David Hervás Marín², Meritxel Fernandez Matilla³, Nagore Fernandez-Llanio Cornella³, Jose Antonio Castellano Cuesta³, Cristobal Antonio Pavez Perales¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Biostatistics Unit. IIS La Fe, Valencia, Spain, ³Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. IL2 is an anti-inflammatory cytokine in SLE, but its loss…
Abstract Number: 2112 • 2018 ACR/ARHP Annual Meeting
IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
Stephanie Lazar¹, Rajaie Namas², Celine C. Berthier³ and Michelle Kahlenberg⁴, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with SLE have increased type I IFN-regulated gene expression in peripheral blood, which has been correlated with systemic disease activity. IFN-regulated gene expression…
Abstract Number: 2684 • 2018 ACR/ARHP Annual Meeting
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Katie Streicher¹, Jixin Wang¹, Philip Z. Brohawn², Brandon W. Higgs², Raj Tummala³ and Koustubh Ranade⁴, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²MedImmune LLC, Gaithersburg, MD, ³MedImmune, Gaithersburg, MD, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Type I interferon has been identified as one of the central mediators in the pathogenesis of SLE, such that patients are characterized by activation…
Abstract Number: 475 • 2018 ACR/ARHP Annual Meeting
Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
Onengiya Harry¹, Angela C Combs², Brooke Hater², Emily Roemisch², Leslie A. Favier³, Najla Aljaberi⁴, Aimee W Smith², Rhyanne McDade², Lauren Fussner⁵, Jennifer L. Huggins⁶, Lori E Crosby² and Avani C Modi⁷, ¹Pediatric Rheumatology, Cincinnati Childrens' Hospital Medical Center, Cincinnati, OH, ²Behavior Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷Center for Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-adherence to medical recommendations in childhood-onset systematic lupus erythematosus (cSLE) is estimated to be between 40-50%. For patients with cSLE, non-adherence results in increased…
Abstract Number: 975 • 2018 ACR/ARHP Annual Meeting
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
KA Casey¹, WI White¹, Nickie L. Seto², Martin Playford³, MA Smith¹, P Carlucci², B Yu⁴, L Wang⁵, G Illei⁴, Nehal Mehta³ and Mariana J. Kaplan², ¹MedImmune, Gaithersburg, MD, ²NIAMS, Bethesda, MD, ³NHLBI, Bethesda, MD, ⁴MedImmune, Gaithersberg, MD, ⁵AstraZeneca, Gaithersburg, MD
Background/Purpose: Cardiovascular disease is a leading cause of death for patients with systemic lupus erythematosus (SLE), and the disease is widely known to feature premature…
Abstract Number: 1699 • 2018 ACR/ARHP Annual Meeting
Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus
May Choi¹, Eric Campbell², Ann E. Clarke¹, Michelle Jung², Claire Barber³, Yvan St.Pierre⁴ and Marvin J. Fritzler¹, ¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: M-phase phosphoprotein (MPP-1), also termed kinesin interacting protein (KIF20B), is a 210 kDa protein that is highly expressed during cell division. Autoantibodies to MPP-1…
Abstract Number: 2120 • 2018 ACR/ARHP Annual Meeting
CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
Jin Kyun Park¹, Ye Ji Lee², Ji Soo Park³, Eun Young Lee⁴, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Department of Immunology, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
CD47-Signal Regulatory Protein-Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus.Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease mediated by unbalanced activation of…
Abstract Number: 2792 • 2018 ACR/ARHP Annual Meeting
The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus
Laura van Dam¹, Zgjim Osmani¹, Tineke Kraaij¹, Sylvia W.A. Kamerling¹, Jaap A. Bakker², Hans U. Scherer³, Ton Rabelink¹, Reinhard Voll⁴, David A. Isenberg⁵, Cees van Kooten¹ and Y.K. Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁵University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease characterized by immune-complexes (ICx) which cause inflammation and damage. Effective targeting of autoantibody secreting…
Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Jocelyn S. Gandelman¹, Omair A. Khan², Megan Shuey³, Jacquelyn E. Neal², Alyson Dickson⁴, April Barnado⁵, Li Wang², William Dupont², C. Michael Stein⁴ and Cecilia P. Chung⁴, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Pharmacology, Vanderbilt University, Nashville, TN, ⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁵Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…

« Previous Page
1
…
7
8
9
10
11
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].